Immunomodulator CTLA4-Ig was set to be the miracle drug for organ transplantation a dozen years ago, but then faded from view. Now, with startling results in rheumatoid arthritis, costimulatory blockers are on a comeback. Ken Garber reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
29 February 2004
An Erratum to this paper has been published: https://doi.org/10.1038/nbt0404-459b
References
Kremer, J.M. et al. N. Engl. J. Med. 349, 1907–1915 (2003).
Lafferty, K.J. & Cunningham, A.J. Aust. J. Exp. Biol. Med. Sci. 53, 27–42. (1975).
Martin, P.J. et al. J. Immunol. 136, 3282–3287 (1986).
Cohen, J. Science 257, 751 (1992).
Waldholz, M. Wall Street Journal August 7 (1992), p. B8.
Oliver, S. Forbes 154, 190, (December 19, 1994).
Davis, S.J. et al. Nat. Immunol. 4, 217–224 (2003).
Mellor, A.L. & Munn, D.H. Immunol. Today 20, 469–473 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Make or break for costimulatory blockers. Nat Biotechnol 22, 145–147 (2004). https://doi.org/10.1038/nbt0204-145
Issue Date:
DOI: https://doi.org/10.1038/nbt0204-145
This article is cited by
-
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Nature Reviews Immunology (2004)
-
Erratum: Make or break for costimulatory blockers
Nature Biotechnology (2004)
